Top

Published in:

01-02-2020 | Ovarian Cancer | Original Article

Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer

Authors: Guodong Zhang, Jiaqi Lu, Moran Yang, Yiying Wang, Haiou Liu, Congjian Xu

Published in: Cancer Immunology, Immunotherapy | Issue 2/2020

Abstract

High grade ovarian serous cancer (HGSC) is a malignant disease with high mortality. Glycosylation plays important roles in tumor invasion and immune evasion, but its effect on the immune microenvironment of HGSC remains unclear. This study examined the association of glycosyltransferase expression with HGSC prognosis and explored the underlying mechanism using clinical specimens and integrated bioinformatic analyses. We identified a cluster of 15 glycogenes associated with reduced overall survival, and GALNT10 was found to be an independent predictor of HGSC prognosis. The high GALNT10 expression was associated with increased regulatory CD4+ T cells infiltration and decreased granzyme B expression in CD8+ T cells. The expression of GALNT10 and its product, Tn antigen, in HGSC specimens was associated with the increased infiltration of M2 macrophages and neutrophils, and the decreased infiltration of CD3+ T cells, NK cells, and B cells. Taken collectively, high GALNT10 expression confers with immunosuppressive microenvironment to promote tumor progression and predicts poor clinical outcomes in HGSC patients.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68(4):284–296. https://doi.org/10.3322/caac.21456 CrossRefPubMedPubMedCentral

Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8(1):1093. https://doi.org/10.1038/s41467-017-00962-1 CrossRefPubMedPubMedCentral

Cancer Genome Atlas Research N (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615. https://doi.org/10.1038/nature10166 CrossRef

Oliveira-Ferrer L, Legler K, Milde-Langosch K (2017) Role of protein glycosylation in cancer metastasis. Semin Cancer Biol 44:141–152. https://doi.org/10.1016/j.semcancer.2017.03.002 CrossRefPubMed

Pinho SS, Reis CA (2015) Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 15(9):540–555. https://doi.org/10.1038/nrc3982 CrossRefPubMed

Rao TD, Fernandez-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, Wang A, Park KJ, Nemieboka B, Xiang J, Lewis JS, Olvera N, Levine DA, Danishefsky SJ, Spriggs DR (2017) Antibodies against specific MUC16 glycosylation sites inhibit ovarian cancer growth. ACS Chem Biol 12(8):2085–2096. https://doi.org/10.1021/acschembio.7b00305 CrossRefPubMedPubMedCentral

Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P (2016) Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR Am J Roentgenol 206(6):1351–1360. https://doi.org/10.2214/ajr.15.15199 CrossRefPubMed

Rodrigues JG, Balmana M, Macedo JA, Pocas J, Fernandes A, de Freitas JCM, Pinho SS, Gomes J, Magalhaes A, Gomes C, Mereiter S, Reis CA (2018) Glycosylation in cancer: selected roles in tumour progression, immune modulation and metastasis. Cell Immunol. https://doi.org/10.1016/j.cellimm.2018.03.007 CrossRefPubMed

10.

Hanson R, Hollingsworth M (2016) Functional consequences of differential O-glycosylation of MUC1, MUC4, and MUC16 (downstream effects on signaling). Biomolecules 6(3). https://doi.org/10.3390/biom6030034 CrossRefPubMedCentral

11.

Brockhausen I (2006) Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 7(6):599–604. https://doi.org/10.1038/sj.embor.7400705 CrossRefPubMedPubMedCentral

12.

Ohyama C (2008) Glycosylation in bladder cancer. Int J Clin Oncol 13(4):308–313. https://doi.org/10.1007/s10147-008-0809-8 CrossRefPubMed

13.

Langbecker D, Janda M (2015) Systematic review of interventions to improve the provision of information for adults with primary brain tumors and their caregivers. Front Oncol 5:1. https://doi.org/10.3389/fonc.2015.00001 CrossRefPubMedPubMedCentral

14.

Stowell SR, Ju T, Cummings RD (2015) Protein glycosylation in cancer. Annu Rev Pathol 10:473–510. https://doi.org/10.1146/annurev-pathol-012414-040438 CrossRefPubMedPubMedCentral

15.

Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, Lavrsen K, Dabelsteen S, Pedersen NB, Marcos-Silva L, Gupta R, Bennett EP, Mandel U, Brunak S, Wandall HH, Levery SB, Clausen H (2013) Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J 32(10):1478–1488. https://doi.org/10.1038/emboj.2013.79 CrossRefPubMedPubMedCentral

16.

Gomes J, Mereiter S, Magalhaes A, Reis CA (2017) Early GalNAc O-glycosylation: pushing the tumor boundaries. Cancer Cell 32(5):544–545. https://doi.org/10.1016/j.ccell.2017.10.010 CrossRefPubMed

17.

Cheng L, Tachibana K, Zhang Y, Guo J, Kahori Tachibana K, Kameyama A, Wang H, Hiruma T, Iwasaki H, Togayachi A, Kudo T, Narimatsu H (2002) Characterization of a novel human UDP-GalNAc transferase, pp-GalNAc-T10. FEBS Lett 531(2):115–121CrossRefPubMed

18.

Zhang Q, Burdette JE, Wang JP (2014) Integrative network analysis of TCGA data for ovarian cancer. BMC Syst Biol 8:1338. https://doi.org/10.1186/s12918-014-0136-9 CrossRefPubMedPubMedCentral

19.

Wu Q, Yang L, Liu H, Zhang W, Le X, Xu J (2015) Elevated expression of N-acetylgalactosaminyltransferase 10 predicts poor survival and early recurrence of patients with clear-cell renal cell carcinoma. Ann Surg Oncol 22(7):2446–2453. https://doi.org/10.1245/s10434-014-4236-y CrossRefPubMed

20.

Sheta R, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Popa I, Bachvarov D (2017) Altered expression of different GalNActransferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. Int J Oncol 51(6):1887–1897. https://doi.org/10.3892/ijo.2017.4147 CrossRefPubMed

21.

Gaziel-Sovran A, Hernando E (2014) miRNA-mediated GALNT modulation of invasion and immune suppression. OncoImmunology 1(5):746–748. https://doi.org/10.4161/onci.19535 CrossRef

22.

Fucikova J, Rakova J, Hensler M, Kasikova L, Belicova L, Hladikova K, Truxova I, Skapa P, Laco J, Pecen L, Praznovec I, Halaska MJ, Brtnicky T, Kodet R, Fialova A, Pineau J, Gey A, Tartour E, Ryska A, Galluzzi L, Spisek R (2019) TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.Ccr-18-4175 CrossRefPubMed

23.

Catakovic K, Klieser E, Neureiter D, Geisberger R (2017) T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal CCS 15(1):1. https://doi.org/10.1186/s12964-016-0160-z CrossRefPubMed

24.

Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N, Shao Y, Darvishian F, Zavadil J, Erlebacher A, Mahal LK, Osman I, Hernando E (2011) miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 20(1):104–118. https://doi.org/10.1016/j.ccr.2011.05.027 CrossRefPubMedPubMedCentral

25.

Wu H, Chen J, Li D, Liu X, Li L, Wang K (2017) MicroRNA-30e functions as a tumor suppressor in cervical carcinoma cells through targeting GALNT7. Transl Oncol 10(6):876–885. https://doi.org/10.1016/j.tranon.2017.08.006 CrossRefPubMedPubMedCentral

26.

Huanna T, Tao Z, Xiangfei W, Longfei A, Yuanyuan X, Jianhua W, Cuifang Z, Manjing J, Wenjing C, Shaochuan Q, Feifei X, Naikang L, Jinchao Z, Chen W (2015) GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7. Mol Carcinog 54(10):1159–1171. https://doi.org/10.1002/mc.22186 CrossRefPubMed

27.

Dahmani A, Delisle JS (2018) TGF-beta in T cell biology: implications for cancer immunotherapy. Cancers (Basel) 10 (6). https://doi.org/10.3390/cancers10060194 CrossRefPubMedCentral

28.

Whiteside TL (2018) FOXP3 + Treg as a therapeutic target for promoting anti-tumor immunity. Expert Opin Therap Targets 22(4):353–363. https://doi.org/10.1080/14728222.2018.1451514 CrossRef

29.

Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49–61. https://doi.org/10.1016/j.immuni.2014.06.010 CrossRefPubMedPubMedCentral

30.

Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51. https://doi.org/10.1016/j.cell.2010.03.014 CrossRefPubMedPubMedCentral

31.

Tariq M, Zhang J, Liang G, Ding L, He Q, Yang B (2017) Macrophage polarization: anti-cancer strategies to target tumor-associated macrophage in breast cancer. J Cell Biochem 118(9):2484–2501. https://doi.org/10.1002/jcb.25895 CrossRefPubMed

32.

Hurt B, Schulick R, Edil B, El Kasmi KC, Barnett C Jr (2017) Cancer-promoting mechanisms of tumor-associated neutrophils. Am J Surg 214(5):938–944. https://doi.org/10.1016/j.amjsurg.2017.08.003 CrossRefPubMed

33.

Sionov RV, Fridlender ZG, Granot Z (2015) The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron 8(3):125–158. https://doi.org/10.1007/s12307-014-0147-5 CrossRefPubMed

34.

Fu C, Zhao H, Wang Y, Cai H, Xiao Y, Zeng Y, Chen H (2016) Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen. HLA 88(6):275–286. https://doi.org/10.1111/tan.12900 CrossRefPubMed

35.

Schultz MJ, Swindall AF, Bellis SL (2012) Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev 31(3–4):501–518. https://doi.org/10.1007/s10555-012-9359-7 CrossRefPubMedPubMedCentral

36.

Ghattass K, El-Sitt S, Zibara K, Rayes S, Haddadin MJ, El-Sabban M, Gali-Muhtasib H (2014) The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway. Molecular Cancer 13:12. https://doi.org/10.1186/1476-4598-13-12 CrossRefPubMedPubMedCentral

37.

Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, Buxton J, Hutson R, Nugent D, Perren TJ (2011) The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obst 284(1):221–227. https://doi.org/10.1007/s00404-010-1655-2 CrossRef

38.

Freire T, Lo-Man R, Bay S, Leclerc C (2011) Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem 286(10):7797–7811. https://doi.org/10.1074/jbc.M110.209742 CrossRefPubMed

39.

Suzuki Y, Sutoh M, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Habuchi T, Arai Y, Fukuda M, Ohyama C, Tsuboi S (2012) MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int J Oncol 40(6):1831–1838. https://doi.org/10.3892/ijo.2012.1411 CrossRefPubMed

40.

Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T (2013) The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology 23(2):178–187. https://doi.org/10.1093/glycob/cws139 CrossRefPubMed

41.

Carrascal MA, Severino PF, Guadalupe Cabral M, Silva M, Ferreira JA, Calais F, Quinto H, Pen C, Ligeiro D, Santos LL, Dall’Olio F, Videira PA (2014) Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Molecular Oncol 8(3):753–765. https://doi.org/10.1016/j.molonc.2014.02.008 CrossRef

42.

Beatson R, Tajadura-Ortega V, Achkova D, Picco G, Tsourouktsoglou TD, Klausing S, Hillier M, Maher J, Noll T, Crocker PR, Taylor-Papadimitriou J, Burchell JM (2016) The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol 17(11):1273–1281. https://doi.org/10.1038/ni.3552 CrossRefPubMedPubMedCentral

43.

Madsen CB, Petersen C, Lavrsen K, Harndahl M, Buus S, Clausen H, Pedersen AE, Wandall HH (2012) Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PLoS One 7(11):e50139. https://doi.org/10.1371/journal.pone.0050139 CrossRefPubMedPubMedCentral

Title: Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer
Authors: Guodong Zhang
Jiaqi Lu
Moran Yang
Yiying Wang
Haiou Liu
Congjian Xu
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Cancer Immunology, Immunotherapy / Issue 2/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02454-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

Lysosomal peptidases in innate immune cells: implications for cancer immunity

Lysyl oxidases: linking structures and immunity in the tumor microenvironment

Immunomodulation by Schwann cells in disease

Potential oncogenic roles of mutant-p53-derived exosomes in the tumor–host interaction of head and neck cancers

Immune biological rationales for the design of combined radio- and immunotherapies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer